clinical trial · NCT05552755
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous PolyposisREC-4881Placebo
brief summary
This is a multicenter, two-part trial in participants with FAP.
started
Jul 10, 2023
primary completion
Jun 1, 2027
completion
Sep 1, 2027
last updated
Apr 16, 2026
detailed description
This is a Phase 1b/2 trial to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of REC-4881 in participants with FAP. This two-part study will treat participants with phenotypic classical FAP with disease involvement of the duodenum or the residual colon/rectum/pouch as the primary disease site.
official title
A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol